These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 4324977)

  • 1. Clinical implications of unnatural amino acids and amines.
    Sjoerdsma A
    Fed Proc; 1971; 30(3):908-11. PubMed ID: 4324977
    [No Abstract]   [Full Text] [Related]  

  • 2. [Parkinson's syndrome. 4 years of experience in treatment with L Dopa associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; de Ajuriaguerra J
    Nouv Presse Med; 1973 Feb; 2(5):315-6. PubMed ID: 4686226
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; Bartholini G; Constantinidis J; Eisenring JJ; Geissbühler F; Yanniotis G; de Ajuriaguerra J
    Schweiz Med Wochenschr; 1973 Oct; 103(42):1466-74. PubMed ID: 4750149
    [No Abstract]   [Full Text] [Related]  

  • 4. [Other trials with drug therapy in parkinsonism].
    Presthus J
    Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2115-7. PubMed ID: 4590072
    [No Abstract]   [Full Text] [Related]  

  • 5. Coupling of hypotensive and anit-Parkinson effects with two dopaminergic drugs.
    Düby SE; Dahl LK; Cotzias GC
    Trans Assoc Am Physicians; 1971; 84():289-96. PubMed ID: 5164305
    [No Abstract]   [Full Text] [Related]  

  • 6. Modification of levodopa effect by systemic decarboxylase inhibition.
    Mars H
    Arch Neurol; 1973 Feb; 28(2):91-5. PubMed ID: 4683155
    [No Abstract]   [Full Text] [Related]  

  • 7. [Inhibitors of catecholamine biosynthesis (review of the literature)].
    Frantsuzova SB
    Farmakol Toksikol; 1973; 36(5):624-8. PubMed ID: 4150865
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pharmacological and therapeutic studies (p-chlorphenylalanin) on carcinoid syndrome in 11 cases].
    von Studnitz W; Waldenström J
    Klin Wochenschr; 1971 Jul; 49(13):748-55. PubMed ID: 4254559
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of Parkinson's disease with L-dopa alone or combined with Ro 4-4602].
    Barbeau A; Gillo-Joffroy L; Mars H; Arsenault A
    Rev Can Biol; 1972; 31():Suppl:169-74. PubMed ID: 5052323
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of parkinsonism with L-dopa and an L-aromatic amino acid inhibitor].
    Streifler M; Vardi J; Kesten M
    Harefuah; 1972 Nov; 83(9):362-4. PubMed ID: 4669737
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacological aspects of the unnatural amino acids and amines. Introductory remarks.
    Horita A
    Fed Proc; 1971; 30(3):857-8. PubMed ID: 4324973
    [No Abstract]   [Full Text] [Related]  

  • 12. The balance of biogenic amines as condition for normal behaviour.
    Birkmayer W; Danielczyk W; Neumayer E; Riederer P
    J Neural Transm; 1972; 33(2):163-78. PubMed ID: 4643007
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association].
    Wajsbort J; Hemli JA; Alfandary I; Yahel M; Siegfried J
    Wien Med Wochenschr; 1971 Oct; 121(42):741-5. PubMed ID: 5115985
    [No Abstract]   [Full Text] [Related]  

  • 14. [Dopa and decarboxylase inhibitors in Parkinson's disease].
    Pakkenberg H
    Ugeskr Laeger; 1974 Feb; 136(7):377. PubMed ID: 4821980
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor].
    Stammler A; Vielhaber K
    Fortschr Neurol Psychiatr Grenzgeb; 1972 Oct; 40(10):564-8. PubMed ID: 4565521
    [No Abstract]   [Full Text] [Related]  

  • 16. Tryptophan hydroxylase inhibitors.
    Koe BK
    Fed Proc; 1971; 30(3):886-96. PubMed ID: 4252531
    [No Abstract]   [Full Text] [Related]  

  • 17. Levadopa and psoriasis.
    Barbeau A; Giroux JM
    Lancet; 1972 Jan; 1(7743):204-5. PubMed ID: 4109575
    [No Abstract]   [Full Text] [Related]  

  • 18. [Experiences in the treatment of Parkinson's disease with a combination drug: L-dopa plus decarboxylase inhibitor (Ro 8-0576)].
    Steinhäusl H
    Wien Med Wochenschr; 1973 Jun; 123(26):433-5. PubMed ID: 4578743
    [No Abstract]   [Full Text] [Related]  

  • 19. Levodopa and Ro 4-4602 in psoriasis.
    Giroux JM; Dubuc R; Barbeau A
    Lancet; 1972 Aug; 2(7772):333-4. PubMed ID: 4115065
    [No Abstract]   [Full Text] [Related]  

  • 20. [Therapy of Parkinson's syndrome with L-dopa per os combined with a decarboxylase inhibitor (Ro 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; De Ajuriaguerra J
    Neurol Neurocir Psiquiatr; 1969; 10(1):1-25. PubMed ID: 5406970
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.